
DEA Issues Final Aggregate Production Quotas For ADHD Treatment Medications

September 4, 2024 - Scheduled for publication tomorrow (Sept. 5, 2024) in the Federal Register, the Drug Enforcement Administration (DEA) will be issuing a Final Order increasing the 2024 aggregate production quotas (APQs) to address domestic and international shortages of ADHD treatment medications. The order becomes effective when published.

A copy of an advance public inspection format is attached to this post.

Adjustments are expressed in grams of anhydrous acid or base and are as follows: Schedule II lisdexamfetamine from 26,500,000 to 32,736,000 and d-amphetamine (for conversion) from 20,000,000 to 23,688,235.

All other schedule I and II controlled substances included in the 2024 established APQ as previously established.

See the notice [here](#).

Don't Forget to Register for Our Upcoming Webinars

The NASCSA Education Committee is pleased to announce a number of exciting webinars offered for members and sponsors in the

President's Message

Dear Members, Sponsors, and Colleagues,

I wanted to drop everyone a quick message to remind you that the NASCSA Annual Conference is just around the corner! Join us in Greenville, South Carolina from October 28-31, 2024, for an engaging and insightful event. This is a fantastic opportunity to connect with fellow professionals, gain valuable knowledge, and learn about current trends in the industry.

If you haven't already, please make sure to register as soon as possible to secure your spot. Don't miss out, as this year's program is packed full of great learning opportunities.

We are pleased to announce Kari Shanard-Koenders has joined the team as NASCSA's new Policy and Communications Director. Kari has had a diverse 40-year career in pharmacy working in the various private sector roles and for the South Dakota Board of pharmacy as Prescription Drug Monitoring Director and later becoming the Executive Director/Secretary of the Board and served as chair of NASCSA's Education Committee in the past.

We look forward to seeing you in Greenville!

Best regards,
Eric Griffin
NASCSA President

Save the Date for NASCSA's Annual Conference 2024!

Mark your calendar! It's hard to believe that plans are well underway for our 40th Annual Conference taking place at the Hyatt Regency in downtown Greenville, South Carolina October 28-31, 2024.

We have some exciting and fun plans for this year's conference as we mark our anniversary, so check the [website](#) on a regular basis for

coming months. We will be adding additional webinars, so please make sure to check the website periodically as well as communications from NASCSA.

Upcoming webinars include the following:

LAST CHANCE - September 11, 2024 – 3-4 pm ET - Rescheduling Marijuana - Will the Grass Really be Greener?

September 18, 2024 – 3-4 pm ET - The Drug Supply Chain Security Act: Are You Really Ready?

October 2 – 3-4 pm ET - 2024 Town Hall - National Association of State Controlled Substances Authorities (NASCSA)

November 7, 2024 - 3-4 pm ET - Stimulants 101: What State Leaders Need to Know

There is no limit to attendees from regular member and associate members to attend any of our webinars, so feel free to pass along information about the webinars to other officials within your organization.

To register visit our website <https://www.nascsa.org/webinars>

Note: webinars are only open to members and sponsors.

Sponsorships Available

NASCSA relies on the generous support from its sponsors to keep the organization strong. If you are interested in becoming a sponsor, please find additional information [here](#). If you are a current sponsor, thank you for your support! We kindly request current sponsors renew your sponsorship as soon as possible.

Conference 2025-2026 Dates Announced – Mark Your Calendars

NASCSA is pleased to announce dates and locations for the 2025 and 2026 annual conference, so please

updates. Conference and hotel registration information is already available online. We anticipate a draft conference program will be available later next month.

NASCSA Welcomes Kari Shanard-Koenders to Our Team



We are delighted to announce that Kari Shanard-Koenders will be joining the team at NASCSA as Policy and Communications Director where she will be working on a variety of projects related to controlled substances and Prescription Monitoring Programs.

Kari holds a pharmacy degree from the University of Kansas. In 2020, Kari completed a Master of Science Degree in Jurisprudence from Seton Hall Law School.

Kari has had a diverse career working as Consultant Pharmacist/Medical Facilities Surveyor for the SD Department of Health, in staff and management roles in hospital, retail, psychiatric, and long-term care pharmacies in Kansas and South Dakota.

Kari joined the SD Board of Pharmacy in July 2012 to become the PDMP Director and in 2015 became its Executive Director/Secretary. Kari served on several NABP committees and Task Forces. She served on the Education Committee and chaired it until April 2024. Kari retired from the Board in May 2024 to enjoy more time with family and friends.

Kari was very honored to be the recipient of the 2022 Bill Ward Education Award from NASCSA and the 2024 Lester E. Hosto Distinguished Service Award from NABP.

Kari lives in Sioux Falls, South Dakota and continues to serve on a variety of committees, boards, for local non-profits, Minnehaha Country Club, Kelly Inns

mark your calendars:

2025 Conference - October 18-23, 2025 - Renaissance New Orleans Arts Hotel - New Orleans, Louisiana

2026 Conference – October 26-29, 2026 – Holiday Inn By the Bay, Portland, Maine

DEA's Annual Threat Assessment Spotlights Electronic Prescribing Fraud and Use of Counterfeit Pills

DEA published its 2024 National Drug Threat Assessment that examined the trends in deaths from certain drugs, the number of seizures documented, and more.

The assessment also noted that between 2021 and 2023, DEA found an increasing number of fraudulent electronic prescriptions (e-scripts) for controlled prescription drugs, with DEA registrants reporting that their registration numbers and identities were used to create fake e-scripts. DEA described their efforts to disrupt drug trafficking networks through initiatives such as Operation Overdrive and Operation OD Justice, as well as the agency's community outreach efforts to raise awareness about the dangers of fentanyl and counterfeit pills.

The document can be found [here](#).

We Need Your Help

Regular members are asked to submit ideas for **resolutions** to be considered at the business meeting at this year's annual conference.

Members should follow the guidelines outlined in the [Bylaws](#) (See Article XII). Proposed resolutions must be submitted to the Bylaws/Resolutions Committee no later than 60 days in advance of the Business Meeting.

Ltd., and Registry Hotel Management. She is excited to continue to work in the legislative and policy area for NASCSA.

2024 Resolutions and Updated Model PMP Act Now Available

Please review the 2024 process for submitting resolutions at the annual business meeting that includes guidelines as well as deadlines that must be followed as the membership considers proposed resolutions during the business meeting. Please see the preliminary [business meeting agenda](#). There are no proposed bylaw changes under consideration this year.

Resolutions under consideration include the following:

1. Resolution 2024-01 - A Resolution In Support of Prescription Monitoring Programs (PMPs)
2. Resolution 2024-02 - A Resolution Encouraging the Sharing of Certain Data With the United States Drug Enforcement Administration (DEA) by Prescription Monitoring Programs (PMPs)
3. Resolution 2024-03 - A Resolution in Support of the Adequate Control of Certain Substances of Misuse and Abuse
4. Resolution 2024-04 - A Resolution in Support of Updating the Model Prescription Monitoring Program (PMP) Act (with attached Model PMP Act)
5. Resolution 2024 - 05 -A Resolution Recognizing Kevin Borchert
6. Resolution 2024-06 - A Resolution Recognizing Kari Shanard-Koenders

The statement of purpose for each resolution, copies of the resolution as well as the Updated Model Prescription Monitoring Program (PMP Model Act) are found [here](#). A limited number of copies will be available onsite so please review and print if possible in advance of the meeting.

[Finally - two important reminders for regular members:](#)

- Please make sure you are present for the first business meeting on Monday, Oct. 28, 2024 promptly at 1:15 pm where a quorum will be established for voting;
- This year we will be streamlining the voting process. Upon registration for the conference, one regular member representative will be given voting cards to be displayed during each vote during the business meeting. If there are multiple representatives from a state, district, commonwealth or territory a single designee should be assigned to vote on behalf of the

Have News?

We would love to hear more from our members about news from your state, territory or district, or industry news of importance. Please pass this information along to kathykeough@nascsa.org.

Check Out NASCA's Youtube Channel

NASCSA maintains its own YouTube Channel where a select number of our webinars are uploaded several months after they take place. Quite a few webinars were recently uploaded, so please visit the YouTube channel and subscribe as well. More information is found [here](#).

Mark Your Calendars

NASCSA is pleased to announce dates and locations for the 2025 and 2026 annual conference, so please mark your calendars:

- 2025 Conference - October 18-23, 2025 - Renaissance New Orleans Arts Hotel - New Orleans, Louisiana
 - 2026 Conference – October 26-29, 2026 – Holiday Inn By the Bay, Portland, Maine
-



Sponsor Spotlight: Guidepost Solutions

state, district, commonwealth or territory.

A special thanks to the Resolutions/Bylaws Committee comprised of chair Sid Seal (Vice President, NASCSA, MS Board of Pharmacy); Larry Houck (Hyman, Phelps & McNamara); Terri Witkowski (IA Board of Pharmacy); Stephanie Mueller (MS Board of Pharmacy); Joe Fontenot (LA Board of Pharmacy) and Shannon Tonn (MN Board of Pharmacy) for all their hard work over the past several months.

The business meeting is open to all and we encourage everyone to attend the meeting. Proposed resolutions will be available prior to this year's conference.

Please sign up for NASCSA's Town Hall on **October 2, 2024 at 3 pm ET** where we will be reviewing each of these documents in detail. This will reduce the amount of time that will have to be spent at the business meeting. Registration information can be found [here](#).

Reminder - Free Continuing Education Available for Pharmacists/Technicians on PMP Data Integrity

Take advantage of this free ACPE accredited educational opportunity providing one hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with the NASCSA, and 12 prescription monitoring program (PMP) administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity. Visit <https://ce.talemhealth.com/a/HLQIJS>

NIDA Report: Cannabis and Hallucinogen Use Among Adults Remained at Historic Highs

August 29, 2024 - The National Institute on Drug Abuse (NIDA) reported that past-year use of cannabis and hallucinogens stayed at historically high levels in 2023 among adults aged 19 to 30 and 35 to 50, according to the [latest findings](#) from the [Monitoring the Future survey](#). In contrast, past-year use of cigarettes remained at historically

Guidepost Solutions is a leader in domestic and international investigations, compliance solutions, monitoring, and security and technology consulting. Our mission is to navigate the intricate challenges our clients face, delivering strategic solutions that are not only effective but also ethically grounded.

In the highly regulated pharmaceutical industry, our company offers a range of expert solutions designed to address critical needs and mitigate potential risks. Our robust drug diversion program and policy development expertise ensures strict compliance with the Controlled Substances Act (CSA) and Code of Federal Regulations (CFR), safeguarding your operations against legal and reputational challenges that can arise from enforcement actions. With a proven track record in the field, we understand the intricacies of regulatory compliance and provide tailored solutions to protect your pharmaceutical enterprise.

Our DEA Regulatory Compliance practice is made up of nationally respected, multi-disciplinary experts including former DEA attorneys and compliance experts, Diversion Investigators, and Special Agents. Our experts can outline the appropriate steps to ensure compliance with the regulatory requirements of a DEA registration and help avoid the financial and reputational risk that can result from noncompliance, including potential enforcement actions. We have successfully worked with our clients to establish compliance programs that have withstood the scrutiny of DEA.

Drug Diversion Misuse Brochure Available

The drug diversion misuse brochure produced by Scripps Safe that lists commonly misused controlled substances as well as non-federally scheduled drugs is now available online [here](#).

low levels in both adult groups. Past-month and daily alcohol use continued a decade-long decline among those 19 to 30 years old, with binge drinking reaching all-time lows. However, among 35- to 50-year-olds, the prevalence of binge drinking in 2023 increased from five and 10 years ago. The Monitoring the Future study is conducted by scientists at the University of Michigan's Institute for Social Research, Ann Arbor, and is funded by the National Institutes of Health.

A copy of NIDA's press release with detailed findings if found [here](#).

Regulatory News

Health and Human Services - On August 16, **HHS** issued a **notice** of its regulatory agenda of prospective rulemakings, including: Medications for the Treatment of Opioid Use Disorder.

2024 Title 21 CFR 1300

The US Government Publishing Office is taking pre-orders for its 2024 paper version of Title 21 Code of Federal Regulations (CFR) Part 1300 to End. The cost is \$29 and includes shipping. This is the section of the CFR owned by DEA for implementation with its more than 2 million registrant community.

Here are dual links to place your order for the paper CFR as well as the e-version.

Link [here](#) to order.
Electronic version [here](#)

Regulatory News: Pain Management & Prescribing Practices

- **Maryland HB 548 and SB 1009** - Enacted May 16, establishes a task force on the responsible use of natural psychedelic substances, including barriers health care practitioners and facilitators may encounter relating to insurance, licensing and credentialing entities, zoning, advertising, and financial services.
- **Tennessee HB 2308 and SB 2297** - Enacted May 1, authorizes nurses and PAs who work in **Health Facilities Commission** (HFC)-licensed hospitals to prescribe buprenorphine products for use in recovery or medication-assisted treatment if certain conditions are

met and allows physicians to oversee more than two nurses or PAs who are rendering this care.

NASCSA in the Media

Follow NASCSA on LinkedIn, Twitter, and YouTube.



Share This Email



Share This Email



Share This Email

Have you listened to our NASCSA Podcasts?

[Listen to a NASCSA Podcast](#)

Contact NASCSA Staff

kathykeough@nascsa.org

Kathy Keough
Executive Director

johngadea@nascsa.org

John Gadea
Webmaster

or visit our website at www.nascsa.org

N.A.S.C.S.A | 276 SW Lake Forest Way | Port St. Lucie, FL 34986 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!